SCHEMBL480953

SCHEMBL480953

COc1ccc(C(C)C(O)(c2cc(C)c(=O)n(C)c2)C(F)(F)F)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 5/20 0.37
BRD4 O60885 6/20 0.35
BRD2 P25440 4/20 0.34
BRD3 Q15059 4/20 0.34
CREBBP Q92793 2/20 0.34
NPBWR1 P48145 2/20 0.34
MCHR1 Q99705 2/20 0.34
PGR P06401 3/20 0.33
RORA P35398 1/20 0.33
RORC P51449 1/20 0.33
RORB Q92753 1/20 0.33
PDE2A O00408 1/20 0.32
HTR2A P28223 1/20 0.31
SLC6A4 P31645 1/20 0.31
KCNH2 Q12809 1/20 0.31
NR3C1 P04150 1/20 0.31
NR3C2 P08235 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MTNR1A P48039 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480720 0.93 BRD4 (0.36) CRHR1BRD4BRD2BRD3CREBBP
SCHEMBL480502 0.86 BRD4 (0.37) CRHR1BRD4PGRRORARORC
SCHEMBL480497 0.86 ESR1 (0.34) BRD4BRD2BRD3CREBBPPGR
SCHEMBL754977 0.86 CYP1A2 (0.32) BRD4PDE2AKMT2A
SCHEMBL480703 0.86 CYP1A2 (0.32) BRD4PDE2AKMT2A
SCHEMBL753353 0.86 S1PR2 (0.34) BRD4MEN1KMT2A
SCHEMBL480687 0.86 S1PR2 (0.34) BRD4MEN1KMT2A
SCHEMBL754978 0.85 PTGER4 (0.33) BRD4MEN1KMT2A
SCHEMBL480632 0.85 PTGER4 (0.33) BRD4MEN1KMT2A
SCHEMBL480608 0.84 P2RX3 (0.35) BRD4PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 CRHR1 3/4885BRD4 3300/4885BRD2 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.